(Bloomberg) — Novo Nordisk A/S signed a deal worth as much as €1.165 billion ($1.3 billion) with Sweden’s Nanexa AB, the latest in a string of small acquisitions as the Danish company tries to ensure it can grow through a looming patent cliff.
Most Read from Bloomberg
The agreement gives the Danish pharmaceutical giant a global exclusive license to Nanexa’s Atomic Layer Deposition drug delivery technology platform it can use for obesity and diabetes treatments, according to a statement from Nanexa. Novo will lead global development and commercialization of products under the deal.
Nanexa shares jumped as much as 161% in early Stockholm trading, while Novo shares added as much as 0.7% in Copenhagen.
The agreement comes days after Novo unveiled a new strategy aimed at restoring growth after losing its lead in the booming obesity market to Eli Lilly & Co. Novo Chief Executive Officer Mike Doustdar said acquisitions will remain part of the push, primarily through bolt-on deals, though Novo has the capacity for larger transactions.
Nanexa’s technology enables controlled, gradual release of medicines, allowing for long-acting injections. That can mean fewer injections, with the drug forming a depot in the body from which it is released over time.
Nanexa and Novo already have a history of cooperation, including a 2022 deal on the Swedish company’s delivery system PharmaShell. In addition, Nanexa’s chairman, Goran Ando, was on Novo’s board from 2005 to 2018, with the last five years as chairman.
The deal includes €615 million in upfront payments, and potential development and regulatory milestones, and covers treatments for obesity, type 2 diabetes and other cardiometabolic diseases. Additional sales milestones could take the total value to €1.165 billion, while Nanexa is also eligible for low single-digit royalties on global net sales, it said.
The deal is the third partnership Novo has signed in just over a week as the Danish giant seeks to refill its pipeline ahead of key patent expirations for Ozempic and Wegovy early in the next decade. All three deals are small and early bets from Novo’s perspective, however, and are for projects that are far from reaching patients: a $1.4 billion partnership with Denmark’s Orbis Medicines ApS, three potential obesity compounds acquired from New York biotech Kallyope Inc. and the Nanexa partnership.
Novo is getting access to a technology it has long wanted, Per Hansen, an investment economist at Nordnet, said in a note to clients. While the deal is important for Novo, it’s “unlikely to be a short-term share price trigger.”
Friday’s jump in Nanexa’s stock was the biggest since the company listed in 2015. The Novo deal’s potential value is more than 10 times Nanexa’s market capitalization based on Thursday’s close.
“It’s certain that it will be a very good day for Nanexa’s shareholders,” Hansen said.
–With assistance from Naomi Kresge.
(Updates to add share price move, context from third paragraph)
Most Read from Bloomberg Businessweek
©2026 Bloomberg L.P.